- £701.05m
- £678.05m
- £145.26m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 26.5 | ||
| PEG Ratio (f) | 1.92 | ||
| EPS Growth (f) | 16.01% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.71 | ||
| Price to Tang. Book | 19.98 | ||
| Price to Free Cashflow | 41.7 | ||
| Price to Sales | 4.61 | ||
| EV to EBITDA | 27.13 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 20.26% | ||
| Return on Equity | 18.08% | ||
| Operating Margin | 12.81% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 54.11 | 68.25 | 86.39 | 118.58 | 145.26 | 163.87 | 182.11 | 24.99% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +39.52 | +66.36 | -5.83 | +42.16 | +13.09 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ergomed PLC is a United Kingdom-based company that is primarily focused on providing specialized services to the biopharmaceutical industry. The Company operates through two segments: Clinical Research Services (CRO) and Pharmacovigilance (PV). Its CRO segment is the process of developing medical therapies, drugs and knowledge for safe use in healthcare. Its PV segment is engaged in the activities relating to the detection, understanding and prevention of adverse effects or other drug-related problems throughout its lifecycle. The Company serves over 100 countries. It operates in North America, United Kingdom and Europe, Middle East and Africa, and Asia. The Company's subsidiaries include PrimeVigilance Inc., PrimeVigilance USA Inc., PrimeVigilance s.r.o., PharmInvent regulatory s.r.o., PrimeVigilance Japan K.K., Haemostatix Limited and Sound Opinion Limited.
Directors
- Miroslav Reljanovic CHM (63)
- Richard Barfield CFO
- Mark Enyedy NED (57)
- Llew Keltner NED (67)
- Michael Spiteri NID (59)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- September 29th, 2000
- Public Since
- July 15th, 2014
- No. of Employees
- 1,437
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
London Stock Exchange- Shares in Issue
- 52,084,254
- Address
- 1 Occam Court, Occam Road, GUILDFORD, GU2 7HJ
- Web
- https://ergomedplc.com/
- Phone
- +44 1483503205
- Auditors
- KPMG
Latest News for ERGO
Upcoming Events for ERGO
Full Year 2023 Ergomed PLC Earnings Release
Similar to ERGO
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
FAQ
As of Today at 18:08 UTC, shares in Ergomed are trading at 1,346.00p. This share price information is delayed by 15 minutes.
Shares in Ergomed last closed at 1,346.00p and the price had moved by +5.65% over the past 365 days. In terms of relative price strength the Ergomed share price has outperformed the FTSE All Share Index by +6.69% over the past year.
The overall consensus recommendation for Ergomed is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Ergomed does not currently pay a dividend.
Ergomed does not currently pay a dividend.
Ergomed does not currently pay a dividend.
To buy shares in Ergomed you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 1,346.00p, shares in Ergomed had a market capitalisation of £701.05m.
Here are the trading details for Ergomed:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: ERGO
Based on an overall assessment of its quality, value and momentum Ergomed is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Ergomed is 1,420.63p. That is 5.54% above the last closing price of 1,346.00p.
Analysts covering Ergomed currently have a consensus Earnings Per Share (EPS) forecast of £0.46 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ergomed. Over the past six months, its share price has outperformed the FTSE All Share Index by +31.85%.
As of the last closing price of 1,346.00p, shares in Ergomed were trading +19.04% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Ergomed PE ratio based on its reported earnings over the past 12 months is 26.5. The shares last closed at 1,346.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Ergomed's management team is headed by:
- Miroslav Reljanovic - CHM
- Richard Barfield - CFO
- Mark Enyedy - NED
- Llew Keltner - NED
- Michael Spiteri - NID